Jaguar Health, Inc. (NASDAQ: JAGX) announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 24, 2026, at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com. The presentation is scheduled for 1:00 PM Eastern and will focus on providing updates on the company's crofelemer development program for rare intestinal failure diseases. This event offers investors an opportunity to engage directly with management and gain insights into Jaguar Health's strategic initiatives and pipeline progress.

The presentation will highlight the development of crofelemer powder for oral solution, targeting rare and orphan gastrointestinal disorders with intestinal failure. Specific indications include microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). Jaguar Health family companies, Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., are spearheading the development and commercialization efforts for these treatments.

Key Event Details

Investors can register for the event through the official conference link. A replay of the webcast will be available following the conclusion of the conference. Additionally, Jaguar Health noted that two crofelemer presentations regarding pediatric intestinal failure patients with MVID and SBS-IF are scheduled for the Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting from June 24-27, 2026.

Jaguar Health, Inc. announced that stockholders approved five proposals at its 2026 Annual Meeting, which was adjourned until June 8, 2026. The company focuses on developing novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal disease states. The approval of all proposals marks a key milestone in the company's corporate governance and strategic direction.

The proposals, detailed in the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (SEC) on April 30, 2026, cover various corporate matters. Stockholders can access the proxy statement and other SEC filings for free at the SEC's website or Jaguar's corporate website. The meeting's adjournment to June 8, 2026, allowed for finalizing voting results.

Jaguar Health's family of companies includes Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., which focus on developing and commercializing crofelemer powder for rare gastrointestinal disorders. Another subsidiary, Magdalena Biosciences, a joint venture with Filament Health Corp., is developing plant-derived prescription medicines for mental health indications.

The company's management, including founder, president & CEO Lisa Conte, is set to present virtually at the Emerging Growth Conference on June 10, 2026. The presentation will be available online, with a replay accessible on EmergingGrowth.com and the Emerging Growth YouTube Channel. This event underscores Jaguar's commitment to engaging with investors and stakeholders.

Jaguar Health's forward-looking statements emphasize its expectations for future growth and development, though these are subject to risks and uncertainties. The company does not plan to publicly update these statements unless required by law. For more information, stakeholders can visit Jaguar Health's official website or those of its subsidiaries.